Moderna and Pfizer certainly face global demands in a very demanding production of a new product. We have no reasons to doubt that they are both ensuring that there is a fair and equitable sharing of doses in these uncertain times. We always said that we would have limited supplies, and we're certainly seeing that.
I see this as a bump in the road, for sure. We have no way of confirming if it's a true statement that they have real difficulties with Moderna supplies, but in our conversations we have clear indications and we have numbers to see a positive trend coming out of this current lack of supplies.